肿瘤标志物在肺癌患者管理中的研究进展

doi:10.3969/j.issn.1006-7795.2015.06.028

摘要/Abstract

摘要： 肺癌已经成为全球范围内因癌症导致死亡的首要原因。肿瘤标志物(tumor marker,TM)表达水平异常往往早于临床影像学表现,由于肿瘤标志物检测方法无创、操作简单、快速出结果、可动态监测等优点,越来越多地被应用于肺癌全过程管理中,表现出其特定的临床应用价值。本文就近年来常用TM在肺癌全过程管理中的作用做一综述。

关键词: 肺癌, 肿瘤标志物, 诊断, 预后, 治疗

Abstract: Lung cancer has the highest world-wide cancer mortality. Tumor markers(TM) are very useful in screening tests that aim to detect cancer early, even before there is any imaging evidence. The screening methods using TMs are noninvasive and simple for operation. They are useful to dynamically screen the disease. Tumor markers can be used to assess the response of a tumor to treatment and for prognosis. Owing to these advantages, TM are extensively used in the management of lung cancer patients. We reviewed the development of TM in the clinical field of lung cancer in recent years, especially in Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer(2015 Version).

Key words: lung cancer, tumor marker, diagnosis, prognosis, treatment

中图分类号:

R734.2

支修益, 姚舒洋. 肿瘤标志物在肺癌患者管理中的研究进展[J]. 首都医科大学学报, 2015, 36(6): 986-991.

Zhi Xiuyi, Yao Shuyang. Tumor markers in the whole management of lung cancer patients[J]. Journal of Capital Medical University, 2015, 36(6): 986-991.

参考文献

[1] Reich J M. Lung-cancer screening[J]. N Engl J Med, 2005,353(20):2194-2195.
[2] Zheng X, Schipper M, Kidwell K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2014,90(3):603-611.
[3] 中华医学会检验医学分会肿瘤标志物专家委员会.肿瘤标志物临床检测的基本原则[J].中华检验医学杂志,2004,27(6):393-398.
[4] 中华检验医学杂志编辑委员会.肿瘤标志物的临床应用建议[J].中华检验医学杂志,2012,35(2):103-105.
[5] Schneider J. Early detection of lung cancers-Comparison of computed tomography, cytology and fuzzy-based tumor markers panels[J]. Cancer Biomark, 2010,6(3-4):149-162.
[6] No author listed. Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers[J]. Anticancer Res, 1999,19(4A):2817-2819.
[7] Molina R, Auge J M, Filella X, et al. Pro-gastrin-releasing peptide(proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer[J]. Anticancer Res, 2005,25(3A):1773-1778.
[8] Molina R, Auge J M, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology[J]. Tumour Biol, 2009,30(3):121-129.
[9] Korse C M, Holdenrieder S, Zhi X Y, et al. Multicenter evaluation of a new progastrin-releasing peptide(ProGRP) immunoassay across Europe and China[J]. Clin Chim Acta, 2015,438:388-395.
[10] 刘运秋,于立群,林江涛.检测肿瘤标志物ProGRP、NSE、CYFRA21-1、CEA对胸腔积液鉴别诊断价值的研究[J].中国肺癌杂志,2006,9(3):4.
[11] Lou E, Johnson M, Sima C, et al. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer[J]. Cancer Biomark, 2014,14(4):207-214.
[12] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(1):67-77.
[13] Goldstraw P. The 7th Edition of TNM in Lung Cancer: what now?[J]. J Thorac Oncol, 2009,4(6):671-673.
[14] Ando S, Kimura H, Iwai N, et al. The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer[J]. Respirology, 2003,8(2):163-167.
[15] Nisman B, Biran H, Ramu N, et al. The diagnostic and prognostic value of ProGRP in lung cancer[J]. Anticancer Res, 2009,29(11):4827-4832.
[16] Schneider J, Philipp M, Velcovsky H G, et al. Pro-gastrin-releasing peptide(ProGRP), neuron specific enolase(NSE), carcinoembryonic antigen(CEA) and cytokeratin 19-fragments(CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases[J]. Anticancer Res, 2003,23(2A):885-893.
[17] Yang H J, Gu Y, Chen C, et al. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis[J]. Clin Chem Lab Med, 2011,49(6):1039-1046.
[18] Wojcik E, Rychlik U, Skotnicki P, et al. Utility of ProGRP determinations in cancer patients[J]. Clin Lab, 2010,56(11-12):527-534.
[19] Okusaka T, Eguchi K, Kasai T, et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer[J]. Clin Cancer Res, 1997,3(1):123-127.
[20] Okada M, Nishio W, Sakamoto T, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease[J]. Ann Thorac Surg, 2004,78(1):216-221.
[21] Ardizzoni A, Cafferata M A, Tiseo M, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer[J]. Cancer, 2006,107(12):2842-2849.
[22] Pujol J L, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients[J]. Br J Cancer, 2004,90(11):2097-2105.
[23] Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrin-releasing peptide(ProGRP) and neuron specific enolase(NSE) in diagnosis and prognosis of small-cell lung cancer(SCLC)[J]. Lung Cancer, 2001,32(1):61-69.
[24] Hirose T, Okuda K, Yamaoka T, et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?[J]. Lung Cancer, 2011,71(2):224-228.
[25] Wojcik E, Kulpa J K, Sas-Korczynska B, et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer[J]. Anticancer Res, 2008,28(5B):3027-3033.
[26] Niho S, Nishiwaki Y, Goto K, et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen[J]. Lung Cancer, 2000,27(3):159-167.
[27] Sunaga N, Tsuchiya S, Minato K, et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer[J]. Oncology, 1999,57(2):143-148.
[28] Wang Q Z, Xu W, Habib N, et al. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy[J]. Curr Cancer Drug Targets, 2009,9(4):572-594.
[29] Vasudevan S, Tong Y, Steitz J A. Switching from repression to activation: microRNAs can up-regulate translation[J]. Science, 2007,318(5858):1931-1934.
[30] Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis[J]. Cancer Cell, 2006,9(3):189-198.
[31] Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B[J]. Proc Natl Acad Sci U S A, 2007,104(40):15805-15810.
[32] Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma[J]. J Clin Oncol, 2009,27(12):2030-2037.
[33] Mitchell P S, Parkin R K, Kroh E M, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008,105(30):10513-10518.
[34] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008,18(10):997-1006.
[35] Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J]. Cancer Res, 2004,64(11):3753-3756.
[36] Yu S L, Chen H Y, Chang G C, et al. MicroRNA signature predicts survival and relapse in lung cancer[J]. Cancer Cell, 2008,13(1):48-57.
[37] Zeng G Q, Zhang P F, Li C, et al. Comparative proteome analysis of human lung squamous carcinoma using two different methods: two-dimensional gel electrophoresis and iTRAQ analysis[J]. Technol Cancer Res Treat, 2012,11(4):395-408.
[38] Zeng G Q, Zhang P F, Deng X, et al. Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics[J]. Mol Cell Proteomics, 2012,11(6):M111. 013946.
[39] Chung K, Nishiyama N, Wanibuchi H, et al. AGR2 as a potential biomarker of human lung adenocarcinoma[J]. Osaka City Med J, 2012,58(1):13-24.
[40] Ueda K, Takami S, Saichi N, et al. Development of serum glycoproteomic profiling technique;simultaneous identification of glycosylation sites and site-specific quantification of glycan structure changes[J]. Mol Cell Proteomics, 2010,9(9):1819-1828.
[41] 杨洋,樊玉霞.非小细胞肺癌血清蛋白质标志物的检测及鉴定[J].中华实验外科杂志,2013,30(8):1577-1579.
[42] 覃慧婵,柳广南.iTRAQ联合LC-MS/MS技术在肺癌标志物研究中的应用[J].中华医学杂志,2013,93(40):3238-3240.
[43] 李晓明,龚国富,段秀群.多肿瘤标志物蛋白芯片在肺癌手术前后的应用评价[J].临床肺科杂志,2013,18(1):173-175.
[44] 陈亚楠,王士祺,斯晓明.多肿瘤标志物蛋白芯片检测系统在肺癌诊断中的临床评价[J].现代肿瘤医学,2011,19(7):1345-1348.
[45] 王卫谦,刘宏旭,石岱旺,等.青年与老年非小细胞肺癌的临床特征及预后比较[J].中国医科大学学报,2014,43(7):661-663.
[46] 田刚,周明术,杭永伦,等.肿瘤标志对肺癌诊断价值PLS-DA和ANN-MPL模型评估[J].中华肿瘤防治杂志,2014,21(5):380-383,392.